153 related articles for article (PubMed ID: 10707793)
1. The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK).
Ghielmini M; Schmitz SF; Bürki K; Pichert G; Betticher DC; Stupp R; Wernli M; Lohri A; Schmitter D; Bertoni F; Cerny T
Ann Oncol; 2000; 11 Suppl 1():123-6. PubMed ID: 10707793
[TBL] [Abstract][Full Text] [Related]
2. Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response.
Foran JM; Cunningham D; Coiffier B; Solal-Celigny P; Reyes F; Ghielmini M; Johnson PW; Gisselbrecht C; Bradburn M; Matthews J; Lister TA
Ann Oncol; 2000; 11 Suppl 1():117-21. PubMed ID: 10707792
[TBL] [Abstract][Full Text] [Related]
3. Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study.
Brugger W; Hirsch J; Grünebach F; Repp R; Brossart P; Vogel W; Kopp HG; Manz MG; Bitzer M; Schlimok G; Kaufmann M; Ganser A; Fehnle K; Gramatzki M; Kanz L
Ann Oncol; 2004 Nov; 15(11):1691-8. PubMed ID: 15520073
[TBL] [Abstract][Full Text] [Related]
4. Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features.
Rasmussen PK
Acta Ophthalmol; 2013 Jul; 91 Thesis 5():1-27. PubMed ID: 24041159
[TBL] [Abstract][Full Text] [Related]
5. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK).
Ghielmini M; Schmitz SF; Cogliatti S; Bertoni F; Waltzer U; Fey MF; Betticher DC; Schefer H; Pichert G; Stahel R; Ketterer N; Bargetzi M; Cerny T;
J Clin Oncol; 2005 Feb; 23(4):705-11. PubMed ID: 15598978
[TBL] [Abstract][Full Text] [Related]
6. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.
Forstpointner R; Dreyling M; Repp R; Hermann S; Hänel A; Metzner B; Pott C; Hartmann F; Rothmann F; Rohrberg R; Böck HP; Wandt H; Unterhalt M; Hiddemann W;
Blood; 2004 Nov; 104(10):3064-71. PubMed ID: 15284112
[TBL] [Abstract][Full Text] [Related]
7. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.
Foran JM; Rohatiner AZ; Cunningham D; Popescu RA; Solal-Celigny P; Ghielmini M; Coiffier B; Johnson PW; Gisselbrecht C; Reyes F; Radford JA; Bessell EM; Souleau B; Benzohra A; Lister TA
J Clin Oncol; 2000 Jan; 18(2):317-24. PubMed ID: 10637245
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma.
Baiocchi RA; Alinari L; Lustberg ME; Lin TS; Porcu P; Li X; Johnston JS; Byrd JC; Blum KA
Cancer; 2011 Jun; 117(11):2442-51. PubMed ID: 24048792
[TBL] [Abstract][Full Text] [Related]
9. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG).
Forstpointner R; Unterhalt M; Dreyling M; Böck HP; Repp R; Wandt H; Pott C; Seymour JF; Metzner B; Hänel A; Lehmann T; Hartmann F; Einsele H; Hiddemann W;
Blood; 2006 Dec; 108(13):4003-8. PubMed ID: 16946304
[TBL] [Abstract][Full Text] [Related]
10. Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma.
Ferrero S; Monitillo L; Mantoan B; Barbero D; Genuardi E; Barbiero S; Bernocco E; Caracciolo D; Ruella M; Drandi D; Zanni M; Renna F; Lobetti Bodoni C; Gueli A; Passera R; Musto P; Boccadoro M; Tarella C; Ladetto M
Ann Hematol; 2013 Nov; 92(11):1503-11. PubMed ID: 23737092
[TBL] [Abstract][Full Text] [Related]
11. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study.
Igarashi T; Kobayashi Y; Ogura M; Kinoshita T; Ohtsu T; Sasaki Y; Morishima Y; Murate T; Kasai M; Uike N; Taniwaki M; Kano Y; Ohnishi K; Matsuno Y; Nakamura S; Mori S; Ohashi Y; Tobinai K;
Ann Oncol; 2002 Jun; 13(6):928-43. PubMed ID: 12123339
[TBL] [Abstract][Full Text] [Related]
12. Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma.
Salles G; Gopal AK; Minnema MC; Wakamiya K; Feng H; Schecter JM; Wang M
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):275-284. PubMed ID: 30795996
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma.
Hess G; Keller U; Scholz CW; Witzens-Harig M; Atta J; Buske C; Kirschey S; Ruckes C; Medler C; van Oordt C; Klapper W; Theobald M; Dreyling M
Leukemia; 2015 Aug; 29(8):1695-701. PubMed ID: 25765545
[TBL] [Abstract][Full Text] [Related]
14. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.
Ahmadi T; Chong EA; Gordon A; Aqui NA; Nasta SD; Svoboda J; Mato AR; Schuster SJ
Cancer; 2014 Jan; 120(2):222-8. PubMed ID: 24122387
[TBL] [Abstract][Full Text] [Related]
15. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.
Nickenig C; Dreyling M; Hoster E; Pfreundschuh M; Trumper L; Reiser M; Wandt H; Lengfelder E; Unterhalt M; Hiddemann W;
Cancer; 2006 Sep; 107(5):1014-22. PubMed ID: 16878325
[TBL] [Abstract][Full Text] [Related]
16. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
[TBL] [Abstract][Full Text] [Related]
17. A systematic review of comparative schedule-related toxicities with maintenance rituximab in follicular and mantle cell lymphomas.
Nabhan C; Ollberding NJ; Villines D; Chiu BC; Caces DB; Valdez TV; Ghielmini M; Hsu Schmitz SF; Smith SM
Leuk Lymphoma; 2014 Jun; 55(6):1288-94. PubMed ID: 23998254
[TBL] [Abstract][Full Text] [Related]
18. Clearing minimal residual disease with rituximab consolidation therapy.
Brugger W
Semin Oncol; 2004 Feb; 31(1 Suppl 2):33-7. PubMed ID: 15042533
[TBL] [Abstract][Full Text] [Related]
19. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK).
Ghielmini M; Rufibach K; Salles G; Leoncini-Franscini L; Léger-Falandry C; Cogliatti S; Fey M; Martinelli G; Stahel R; Lohri A; Ketterer N; Wernli M; Cerny T; Schmitz SF
Ann Oncol; 2005 Oct; 16(10):1675-82. PubMed ID: 16030029
[TBL] [Abstract][Full Text] [Related]
20. Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long-term follow-up.
Papajík T; Jedlicková K; Kriegová E; Jarosová M; Raida L; Faber E; Hubácek J; Vondráková J; Pikalová Z; Indrák K
Neoplasma; 2001; 48(6):501-5. PubMed ID: 11949845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
